Drug intelligence / Profile preview

letaxaban

Development stage: Phase 2
Lead developer: Takeda
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Letaxaban (TAK-442) is an investigational oral anticoagulant developed as a direct factor Xa inhibitor. It was primarily studied for the prevention and treatment of thromboembolic events in patients with acute coronary syndromes and arterial thrombosis. Letaxaban acts by selectively inhibiting factor Xa, a key enzyme in the coagulation cascade responsible for converting prothrombin to thrombin, thereby reducing blood clot formation. The drug was developed by Takeda Pharmaceutical and reached phase 2 clinical trials but has not advanced to later stages or received regulatory approval[8].

Brand names: letaxaban
Other names: TAK-442TAK442TAK 442letaxaban

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on letaxaban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on letaxaban.

Explore the full profile